Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1

Anti-PD1/PDL1 monotherapy has failed to acquire sufficiently ideal results in most solid tumors. Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on some tumors, but the functions of MSCs in colorectal cancer (CRC) need further research. In this study, we aimed to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jize, Ma, Xiaomin, Liu, Chuxuan, Cheng, Yang, Li, Bingjun, Zhang, Wenjie, Zeng, Runzhi, Chen, Qishuai, Zhang, Yun, Hu, Sanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944415/
https://www.ncbi.nlm.nih.gov/pubmed/36843945
http://dx.doi.org/10.3389/fphar.2023.1136614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944415/
https://www.ncbi.nlm.nih.gov/pubmed/36843945
http://dx.doi.org/10.3389/fphar.2023.1136614

Ejemplares similares